With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

Doctors & patients confirm acute shortage of the drug in hospitals, even as manufacturer Novartis maintains there is no ...

William Blair analyst Sami Corwin has maintained their bullish stance on CRSP stock, giving a Buy rating yesterday. Sami Corwin’s rating ...

Doctors stress the importance of awareness and testing for thalassemia, a genetic blood disorder affecting children, as cases continue to rise due to lack of information and government programs.

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and ...

My son won’t need monthly hospital trips anymore.""I’m happy to be better and grateful to the doctors," said Vuong, touching ...

In-depth interviews and an online survey found support for gene therapy as a treatment for inherited blood disorders, but ...

He added that Thalassemia incidences are increasing in Sabah, and the cost for lifetime treatment can reach RM3mil per ...

Results from Phase 3 ENERGIZE-T Study of Mitapivat in Transfusion-dependent Thalassemia will be Presented in Oral Session –– Tebapivat Phase 1 ...

Azerbaijan's First Vice-President and the President of the Heydar Aliyev Foundation, Mehriban Aliyeva, visited the ...

BAKU, Azerbaijan, October 31. Mehriban Aliyeva, First Vice-President of the Republic of Azerbaijan and President of the ...